58 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
12 Feb 24
Regulation FD Disclosure
5:23pm
: Retina Specialists [~3k]) Estimated total cost to US healthcare system in 2019: $3.7B Retinitis Pigmentosa A Disease with No Available Treatments
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
or age-related orphan retinal diseases, today announced that it has entered into a securities purchase agreement with healthcare focused institutional … approximately $30 million upon exercise of accompanying warrants at the election of the investors.
The financing includes participation from new healthcare
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
, statutes, rules, regulations, ordinances, orders, judgments and other pronouncements pertaining to the pharmaceutical industry or the healthcare
8-K
EX-99.2
KPRX
Kiora Pharmaceuticals Inc
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
patients in US (Provider: Retina Specialists [~3k]) Estimated total cost to US healthcare system in 2019: $3.7B Retinitis Pigmentosa A Disease
8-K
EX-99.1
ufsz2wcmt5x8uvb1ztm0
9 Nov 23
Regulation FD Disclosure
7:02am
424B1
kcivoaaps fqflq
2 Jun 23
Prospectus with pricing info
5:08pm
FWP
kvzryrw 6ukg
15 May 23
Free writing prospectus
5:18pm
424B3
n3ll8fu4ha2c
28 Dec 22
Prospectus supplement
4:48pm
424B1
4w7kbogr luqjc
22 Jul 22
Prospectus with pricing info
6:00pm